Osimertinib Recruiting Phase 2 Trials for Metastatic Brain Tumors / Non-small Cell Lung Cancer (NSCLC), Stage IV Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03769103Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC